- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07942428
Enzymatic Treatment for Postoperative Nasal Fibrosis After Rhinoplasty
A Fixed-Sequence Crossover Clinical Trial Evaluating Enzymatic Treatment for Mild-to-Moderate Postoperative Nasal Fibrosis After Rhinoplasty
This single-arm, fixed-sequence clinical trial will evaluate an enzymatic preparation for mild-to-moderate postoperative fibrosis of the nasal soft-tissue envelope after rhinoplasty. Each participant will first receive 3 mL of sterile saline injected into the affected nasal area. Two weeks later, clinical assessment and high-resolution nasal ultrasonography, including elastography, will be performed, after which the participant will receive a 3-mL enzymatic preparation in the same affected area. A second clinical assessment and ultrasound examination will be performed 2 weeks after the enzymatic treatment. Changes during the saline and enzymatic treatment periods will be compared within each participant.
Visão geral do estudo
Status
Descrição detalhada
Adults with mild-to-moderate fibrosis of the nasal soft-tissue envelope after rhinoplasty will receive two interventions in a fixed sequence. During Period 1, 3 mL of sterile saline will be injected into the affected nasal area. At 2 weeks, clinical assessment and high-resolution nasal ultrasonography, including elastography, will be performed. The enzymatic preparation will then be injected into the same affected area. It will contain recombinant lipase, collagenase, and hyaluronidase and will be prepared by adding 1.5 mL of high-molecular-weight hyaluronic acid, waiting approximately 5 minutes, and then adding 1.5 mL of sterile saline, for a total volume of 3 mL. Two weeks after the enzymatic treatment, clinical assessment and ultrasound, including elastography, will be repeated. All participants will receive saline first and the enzymatic preparation second.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Minyor Avellaneda, MD, Plastic surgeon
- Número de telefone: +57 (320) 767 4006
- E-mail: contacto@nuarabelleza.com
Locais de estudo
-
-
Bogota D.C.
-
Bogotá, Bogota D.C., Colômbia, 110121
- Recrutamento
- NUARA
-
Contato:
- Minyor Avellaneda, MD, Plastic surgeon
- Número de telefone: +57 (320) 767 4006
- E-mail: contacto@nuarabelleza.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Adults aged 18 years or older. History of rhinoplasty performed at least 3 months before enrollment. Complete healing of the surgical wounds at enrollment. Mild-to-moderate fibrosis of the nasal soft-tissue envelope in an identifiable affected area, diagnosed by clinical examination and documented by baseline high-resolution nasal ultrasonography.
Ability and willingness to provide written informed consent. Ability and willingness to complete the study assessments and follow-up visits.
Exclusion Criteria:
- Severe nasal fibrosis or deformity requiring surgical correction or urgent treatment.
Active infection, open wound, ulceration, or tissue necrosis in the proposed injection area.
Previous injection or other treatment specifically for nasal fibrosis Known hypersensitivity to any component of the enzymatic preparation or to sterile saline.
Pregnancy or breastfeeding. Any medical condition that, in the investigator's judgment, makes study injections unsafe or prevents reliable completion of study assessments.
Inability to provide informed consent or comply with study procedures.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Fixed Sequence: Saline Followed by Enzymatic Treatment
All participants will first receive 3 mL of sterile saline injected into the affected nasal area. Two weeks later, after clinical assessment and ultrasound, they will receive 3 mL of a recombinant enzymatic preparation containing lipase, collagenase, and hyaluronidase, injected into the same affected area. The enzymatic preparation will be reconstituted with 1.5 mL of high-molecular-weight hyaluronic acid, followed approximately 5 minutes later by 1.5 mL of sterile saline. Final ultrasound and clinical assessment will be performed 2 weeks after the enzymatic treatment. |
A total volume of 3 mL of sterile saline injected into the affected nasal area once at the beginning of the study. A total volume of 3 mL containing recombinant lipase, collagenase, and hyaluronidase, injected into the affected nasal area 2 weeks after the saline injection. The preparation will be made by adding 1.5 mL of high-molecular-weight hyaluronic acid, waiting approximately 5 minutes, and then adding 1.5 mL of sterile saline. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Difference in change in nasal soft-tissue thickness between the saline and enzymatic treatment periods
Prazo: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
High-resolution nasal ultrasonography will be used to measure soft-tissue thickness at the prespecified affected area. Measurements will be obtained before saline treatment, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment. The change during the enzymatic period will be compared with the change during the saline period within each participant. Thickness will be recorded in millimeters. |
Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Difference in change in nasal soft-tissue elastography measurements between treatment
Prazo: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
Elastography will be recorded at the prespecified affected area at baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment. The change during the enzymatic period will be compared with the change during the saline period within each participant. The elastography parameter and units reported by the ultrasound system will be specified in the study protocol. |
Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
|
Change in structural characteristics of the nasal soft-tissue envelope
Prazo: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
Structural characteristics of the previously operated nasal soft-tissue envelope at the affected area will be assessed by high-resolution nasal ultrasonography at each study assessment. |
Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
|
Treatment-emergent adverse events
Prazo: Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
Adverse events reported or observed after saline and enzymatic injections, including local pain, swelling, erythema, skin changes, infection, tissue injury, or other adverse events. |
Baseline, 2 weeks after saline treatment and before enzymatic treatment, and 2 weeks after enzymatic treatment
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- Nascimento NS, Torres-Obreque KM, Oliveira CA, Rabelo J, Baby AR, Long PF, Young AR, Rangel-Yagui CO. Enzymes for dermatological use. Exp Dermatol. 2024 Jan;33(1):e15008. doi: 10.1111/exd.15008.
- Shekhter AB, Balakireva AV, Kuznetsova NV, Vukolova MN, Litvitsky PF, Zamyatnin AA Jr. Collagenolytic Enzymes and their Applications in Biomedicine. Curr Med Chem. 2019;26(3):487-505. doi: 10.2174/0929867324666171006124236.
- Menick FJ, Salibian A. Primary intranasal lining injury cause, deformities, and treatment plan. Plast Reconstr Surg. 2014 Nov;134(5):1045-1056. doi: 10.1097/PRS.0000000000000694.
- Kryczka J, Boncela J. Proteases Revisited: Roles and Therapeutic Implications in Fibrosis. Mediators Inflamm. 2017;2017:2570154. doi: 10.1155/2017/2570154. Epub 2017 May 31.
- Afratis NA, Klepfish M, Karamanos NK, Sagi I. The apparent competitive action of ECM proteases and cross-linking enzymes during fibrosis: Applications to drug discovery. Adv Drug Deliv Rev. 2018 Apr;129:4-15. doi: 10.1016/j.addr.2018.03.004. Epub 2018 Apr 5.
- Sharif-Askary B, Carlson AR, Van Noord MG, Marcus JR. Incidence of Postoperative Adverse Events after Rhinoplasty: A Systematic Review. Plast Reconstr Surg. 2020 Mar;145(3):669-684. doi: 10.1097/PRS.0000000000006561.
- Hacker S, Pollock J, Gubisch W, Haack S. Differences between Primary and Revision Rhinoplasty: Indications, Techniques, Grafts, and Outcomes. Plast Reconstr Surg. 2021 Sep 1;148(3):532-541. doi: 10.1097/PRS.0000000000008216.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 027
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
non considered in the patient informed consent
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .